Literature DB >> 23993831

Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes.

R Peter1, G Dunseath, S D Luzio, D R Owens.   

Abstract

AIMS: To re-examine the relative and absolute contributions of fasting/pre-prandial glucose (FPG) and post-prandial glucose (PPG) to 24-h hyperglycaemia and HbA1c respectively in non-insulin treated subjects with type 2 diabetes (T2DM).
MATERIALS AND METHODS: A total of 52 T2DM subjects (37 men) had daytime 12h plasma glucose (PG) profiles determined in response to three serial identical test meals commencing at 08 00h with pre-prandial and frequent post-prandial blood samples collected. The overnight PG profile was derived by projecting the 20 00h glucose concentration to the pre-breakfast value at 08 00h. PPG exposure was calculated above fasting/pre-prandial value for each meal. Excess hyperglycaemia was calculated based on a PG>5.5mmol/L with fasting hyperglycaemia being the difference between the two measurements. The subjects were divided into five groups according to the HbA1c (Group 1<7.0%; Group 2: 7.0-<7.5; Group 3: 7.5-<8.0%; Group 4: 8.0-<9.0%; Group 5:≥9.0%). The 24h relative contribution of PPG exposure and fasting hyperglycaemia to excess hyperglycaemia and the absolute contribution of PPG and fasting hyperglycaemia to excess HbA1c (HbA1c - 5.1%) was calculated.
RESULTS: With deteriorating glycaemia, the relative contribution of PPG exposure decreased across the groups from 43.5% (HbA1c<7.0%) to 17.8% (HbA1c≥9.0%), whilst the contributions of fasting hyperglycaemia increased from 56.5% to 82.2% (P=0.004), respectively. The absolute contributions of PPG to excess HbA1c was 0.7%, which remained relatively stable across the spectrum of HbA1c, whilst fasting hyperglycaemia increased significantly from groups 1 to 5 (P<0.001).
CONCLUSIONS: Fasting hyperglycaemia contributes substantially in all groups, increasing as HbA1c deteriorates. The absolute contribution of PPG to excess HbA1c did not vary across the range of HbA1c, representing a significant relative contribution even in well-controlled subjects with a HbA1c<7.0%.
Copyright © 2013. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Fasting glycaemia; Glycémie post-prandiale; Glycémie à jeun; HbA(1c); Hyperglycaemia; Hyperglycémie; Post-prandial glycaemia

Mesh:

Substances:

Year:  2013        PMID: 23993831     DOI: 10.1016/j.diabet.2013.07.001

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  4 in total

1.  Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.

Authors:  Rimei Nishimura; Yuko Tanaka; Kazuki Koiwai; Kohei Inoue; Thomas Hach; Afshin Salsali; Søren S Lund; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2015-01-30       Impact factor: 9.951

2.  Relationship of glycated hemoglobin, and fasting and postprandial hyperglycemia in type 2 diabetes mellitus patients in Malaysia.

Authors:  Lee Ling Lim; Alan Jm Brnabic; Siew Pheng Chan; Luqman Ibrahim; Sharmila Sunita Paramasivam; Jeyakantha Ratnasingam; Shireene Ratna Vethakkan; Alexander Tong Boon Tan
Journal:  J Diabetes Investig       Date:  2016-12-27       Impact factor: 4.232

3.  A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.

Authors:  Denis Raccah; Engels Chou; Stephen Colagiuri; Zsolt Gaàl; Fernando Lavalle; Ashot Mkrtumyan; Elena Nikonova; Nikolaos Tentolouris; Josep Vidal; Melanie Davies
Journal:  Diabetes Metab Res Rev       Date:  2016-10-13       Impact factor: 4.876

4.  Effect of Consuming Oat Bran Mixed in Water before a Meal on Glycemic Responses in Healthy Humans-A Pilot Study.

Authors:  Robert E Steinert; Daniel Raederstorff; Thomas M S Wolever
Journal:  Nutrients       Date:  2016-08-26       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.